The company belongs to the small-cap category with a market capitalization of ₹1,875 crore. On April 12th, company shares closed at ₹648 per share, down 3.45 percent from the previous close price on the stock exchange.
Amrutanjan Health Care Ltd (AHCL) stands as a frontrunner in India’s over-the-counter (OTC) market, recognized among the nation’s top 100 trusted brands. It holds the prestigious position of being the foremost choice in the Modern Trade Head category, commanding an impressive volume market share of 41%.
Furthermore, in the realm of pain management, particularly in products like balms, sprays, and ointments, Amrutanjan holds a commanding market share of 43.3%.
Amrutanjan Health Care Ltd (AHCL) introduced roll-on format products known as “Roll-Ons” in their product line. These roll-on products, such as the Amrutanjan Headache Faster Relaxation Roll-On and the Amrutanjan Back Pain Roll-On, will have a significant market share of 72% within this specific format by December 2023.
Amrutanjan Health Care Ltd manufactures ayurvedic balm for pain management. The company is more than 120 years old and is into over-the-counter (OTC) products in the segments of pain management, women’s hygiene, and packaged fruit juice drinks.
Amrutanjan has three segments through which it caters to its customers: Pain and congestion Management, Beverages, and Women’s Hygiene.
The company operates three manufacturing units, two dedicated to OTC products and one for beverages. With a production capacity of 1,600 MT in the OTC manufacturing units, it is currently enhancing its beverage plant with cutting-edge machinery.
As of Q4 FY22, the company’s pain management products are available in over 12 lakh outlets nationwide. Under ‘Project M5K,’ the company aims to enlist 5,000 distributors, super stockists, and sub-stockists. In FY22 alone, it successfully onboarded approximately 150 super-stockists and 1,200 sub-stockists, extending its reach to smaller towns and villages.
Over the past 12 months, shares of Amrutanjan Health Care Ltd. have appreciated by 8.3%, and over the last five years, they have surged by an impressive 107%. In the third quarter of the fiscal year, the company demonstrated robust sales growth, marking a 19% increase from ₹98 crores in Q3FY23 to ₹117 crores in Q3FY24.
Concurrently, the company achieved significant net profit growth of 55%, rising from ₹11 crores to ₹17 crores during the same period.
Written by Omkar Chitnis
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
